| Study | Chemotherapy agents | Number of eyes | Primary number of eyes | Secondary number of eyes | Follow-up duration (months) | County/region | Design |
| Abramson, et al. 2016 | Melphalan, topotecan, carboplatin, and methotrexate | 120 | 60 | 60 | 36.0 | USA | Retrospective | Akyüz, et al. 2015 | Melphalan | 56 | 12 | 44 | 11.9 | Turkey | Retrospective | Chen, et al. 2017 | Melphalan, topotecan, and carboplatin | 107 | 30 | 77 | 13.6# | China | Retrospective | Chen, et al. 2016 | Melphalan, topotecan, and carboplatin | 13 | 13 | NA | 28# | China | Retrospective | Francis, et al. 2018 | Melphalan, topotecan, and carboplatin | 436 | 228 | 208 | 23.6 | USA | Retrospective | Funes, et al. 2018 | Melphalan, topotecan, and carboplatin | 97 | 35 | 62 | 48.7 | Argentina | Retrospective | Ghassemi, et al. 2014 | Melphalan, topotecan, and carboplatin | 24 | 6 | 18 | 17 | Iran | Retrospective | Gobin, et al. 2011 | Melphalan, topotecan, carboplatin, and methotrexate | 91 | 43 | 48 | 13.0 | USA | Retrospective | Hua, et al. 2018 | Melphalan and topotecan | 84 | 0 | 84 | 14.2# | China | Retrospective | Kiratli, et al. 2018 | Melphalan and topotecan | 30 | 30 | NA | 4.0# | Turkey | Retrospective | Leal-Leal, et al. 2016 | Melphalan and topotecan | 11 | 0 | 11 | 14.3# | Mexico | Retrospective | Li, et al. 2021 | Melphalan, topotecan, and carboplatin | 73 | NA | NA | 7 | China | Retrospective | Liu, et al. 2020 | Melphalan, topotecan, and carboplatin | 14 | 1 | 13 | 17.0 | Malaysia | Retrospective | Marr, et al. 2012 | Melphalan, topotecan, and carboplatin | 26 | 26 | NA | 14# | USA | Retrospective | Michaels, et al. 2016 | Melphalan, topotecan, and carboplatin | 19 | 7 | 12 | 13.0 | USA | Retrospective | Muen, et al. 2012 | Melphalan | 15 | 0 | 15 | 9 | UK | Retrospective | Munier, et al. 2011 | Melphalan | 13 | 9 | 4 | 7.0 | Switzerland | Retrospective | Munier, et al. 2017 | Melphalan | 25 | 25 | NA | 41.7# | Switzerland | Retrospective | Ong, et al. 2015 | Melphalan | 17 | 6 | 11 | 22 | Taiwan | Retrospective | Oporto, et al. 2021 | Melphalan and topotecan | 35 | NA | NA | 36.5 | Chile | Retrospective | Parareda, et al. 2014 | Melphalan | 12 | 12 | NA | 29.5 | Spain | Prospective | Peterson, et al. 2011 | Melphalan | 17 | 0 | 17 | 8.6# | USA | Retrospective | Reddy, et al. 2017 | Melphalan and topotecan | 9 | 0 | 9 | 21.0 | UK | Retrospective | Rishi, et al. 2017 | Melphalan and topotecan | 10 | 2 | 8 | 26.0 | India | Retrospective | Rishi, et al. 2020 | Melphalan and topotecan | 24 | 7 | 17 | 28.6 | India | Retrospective | Rojanaporn, et al. 2019 | Melphalan, topotecan, and carboplatin | 27 | 7 | 20 | 32# | Thailand | Retrospective | Shields, et al. 2014 | Melphalan, topotecan, and carboplatin | 70 | 36 | 34 | 19.0 | USA | Retrospective | Shields, et al. 2021 | Melphalan, topotecan, and carboplatin | 341 | 160 | 207 | NA | USA | Retrospective | Suzuki, et al. 2011 | Melphalan | 408 | 50 | 358 | 74.0 | Japan | Retrospective | Taich, et al. 2014 | Melphalan and topotecan | 27 | 5 | 22 | 11.7 | Argentina | Retrospective | Thampi, et al. 2013 | Melphalan | 20 | 12 | 8 | 15 | USA | Retrospective | Tuncer, et al. 2016 | Melphalan | 24 | 24 | NA | 29 | Turkey | Retrospective | Venturi, et al. 2013 | Melphalan | 41 | 17 | 24 | 13.0 | Italy | Retrospective |
|
|